• 114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

  • May 3 2024
  • Length: 20 mins
  • Podcast

114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development cover art

114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

Listen for free

View show details

  • Summary

  • Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Justin Klee and Josh Cohen, cofounders and cochief executive officers of Amylyx Pharmaceuticals, sat down at the recently concluded AAN Annual Meeting to discuss the results from the pivotal phase 3 PHOENIX trial (NCT) of AMX0035 (Relyvrio) in patients with amyotrophic lateral sclerosis (ALS). The duo provided clarity on the findings, positive takeaways from the disappointing data, and the lessons learned in ALS drug development. In addition, the two provided commentary on the future plans of the therapy in other tauopathies like progressive supranuclear palsy and neurologic conditions like Wolfram syndrome. Furthermore, Klee and Cohen shared thoughts on the company's drug pipeline, including AMX0114, an antisense oligonucleotide in development for patients with ALS.

    Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

    Episode Breakdown:
    • 1:05 – Decision behind removing AMX0035 from market
    • 3:00 – Lessons from PHOENIX, AMX0035 drug development program
    • 6:45 – Unraveling PHOENIX study data
    • 10:00 – Neurology News Minute
    • 12:10 – Potential of AMX0035 in other tauopathies, neurologic conditions
    • 15:00 – Outlook of antisense oligonucleotide AMX0114 in ALS

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Diazepam Buccal Film’s Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD
    • Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
    • FDA Approves Sprinkle Formulation of Neurocrine Biosciences’ Valbenazine for Tardive Dyskinesia or Huntington disease Chorea

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living Science
Show More Show Less

What listeners say about 114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.